Clinical trial
The Role of Interferon Gamma Releasing Assays (IGRA) in Screening and Monitoring for Tuberculosis During Anti-TNF Therapy in Patients With Immune-mediated Inflammatory Disease (IMID)
NCT02135289 is registered in ClinicalTrials.gov with Chinese University of Hong Kong as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Role of Interferon Gamma Releasing Assays (IGRA) in Screening and Monitoring for Tuberculosis During Anti-TNF Therapy in Patients With Immune-mediated Inflammatory Disease (IMID)
- Lead sponsor
- Chinese University of Hong Kong
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 31, 2012
- Completion date
- July 31, 2019
- Enrollment
- 9,160 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
crohn disease, immune-mediated inflammatory disease, inflammatory bowel disease, tuberculosis, ulcerative colitis